Yu Fan Purchases Shares of 1,222,202 CeriBell (NASDAQ:CBLL)

Yu Fan bought a new stake in CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,222,202 shares of the company's stock, valued at approximately $31,631,000. CeriBell accounts for 55.8% of Yu Fan's investment portfolio, making the stock its biggest holding. Yu Fan owned approximately 3.41% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. TPG GP A LLC purchased a new position in shares of CeriBell in the 4th quarter valued at approximately $102,677,000. RTW Investments LP purchased a new position in CeriBell during the fourth quarter valued at $3,882,000. Red Tree Management LLC purchased a new position in CeriBell during the fourth quarter valued at $57,083,000. Redmile Group LLC purchased a new position in CeriBell during the fourth quarter valued at $11,264,000. Finally, Parkman Healthcare Partners LLC purchased a new position in CeriBell during the fourth quarter valued at $828,000.

CeriBell Stock Down 3.9%

Shares of CeriBell stock traded down $0.68 on Friday, reaching $16.58. The company's stock had a trading volume of 211,770 shares, compared to its average volume of 277,143. The firm's fifty day simple moving average is $17.15 and its two-hundred day simple moving average is $22.11. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The business had revenue of $20.49 million during the quarter, compared to the consensus estimate of $19.30 million. Equities analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $16.96, for a total value of $424,000.00. Following the completion of the sale, the chief executive officer now owns 727,151 shares of the company's stock, valued at $12,332,480.96. The trade was a 3.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders sold 49,700 shares of company stock valued at $796,434. Corporate insiders own 20.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CBLL shares. LADENBURG THALM/SH SH started coverage on CeriBell in a research note on Friday, April 4th. They set a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell presently has an average rating of "Buy" and an average target price of $32.50.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.